You are here

Pharma Intelligence

NEW YORK, Feb. 10, 2020 /PRNewswire/ --

Overview
In 2018, combined sales of inhaled asthma and COPD devices in the countries covered by this analysis totaled approximately $10.4bn. Over the forecast period covered by this analysis, total sales are expected to increase at a CAGR of 3.0%, reaching an estimated $12.1bn in 2023 This comprehensive market and medical technology report provides an overview of the inhalation-based devices used in the management of asthma and chronic obstructive pulmonary disease (COPD), and includes an in-depth, product-specific market analysis. Countries covered by this report comprise the US, the five major EU markets (France, Germany, Italy, Spain, and the UK), and Japan. Medical devices covered by this analysis include metered dose inhalers (MDIs) and dry powder inhalers (DPIs) for the treatment of asthma and COPD. This report provides the following useful information:

Read the full report: https://www.reportlinker.com/p05824942/?utm_source=PRN

respiratory disease treatment overview
key epidemiology data on the prevalence of asthma and COPD in major world regions
related product portfolios offered by leading manufacturers
top selling inhalation drug delivery devices, as well as emerging products under development
in-depth market and competitive analyses.

Read the full report: https://www.reportlinker.com/p05824942/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/pharma-intelligence-301001755.html

SOURCE Reportlinker